Research programme: recombinant human MASP-2 - Helion Biotech

Drug Profile

Research programme: recombinant human MASP-2 - Helion Biotech

Latest Information Update: 30 Nov 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Helion Biotech
  • Class Recombinant proteins
  • Mechanism of Action MASP2 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Infections

Most Recent Events

  • 30 Nov 2010 Discontinued - Preclinical for Infections in Denmark (Parenteral)
  • 12 Nov 2008 This programme is available for licensing (
  • 12 Nov 2008 Preclinical trials in Infections in Denmark (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top